Cholestatic pruritus is a common symptom of primary biliary cholangitis (PBC), a rare autoimmune liver disease. Researchers are looking to establish the safety and efficacy of linerixibat – an ...

(Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

The European Commission approved Livmarli oral solution for the treatment of PFIC in patients aged three months and above in July 2024. The drug is also approved for treating cholestatic pruritus ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver ... patients with cholestatic pruritus (relentless itch).

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older.

The impressive growth of cholestatic pruritus market from $19.20 billion in 2024 to an estimated $20.28 billion in 2025. This rapid growth is fuelled by augmenting prevalence of skin disorders ...

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.

LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan “We are thrilled to see ...